Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06793215 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT06793215 is a Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 600 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 14 states.
The verdict
NCT06793215, a Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Divarasib
Study Locations (20)
California
- Marin Cancer Care Inc - Greenbrae
- Hoag Memorial Hospital - Newport Beach
Florida
- BioResearch Partner - Hialeah
- Ascension Sacred Heart - Pensacola
Georgia
- Piedmont Cancer Institute, PC - Atlanta
- Summit Cancer Care PC - Savannah
Illinois
- Affiliated Oncologists, LLC - Chicago Ridge
- Hope and Healing Cancer Services - Hinsdale
New York
- Montefiore Einstein Cancer Center - The Bronx
- Clinical Research Alliance - Westbury
Pennsylvania
- St. Luke's University Health Network - Bethlehem
- Reading Hospital - McGlinn Cancer Institute - West Reading
Alaska
- Alaska Oncology and Hematology - Anchorage
Idaho
- St. Luke's Cancer Institute - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2030-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06793215
The ClinicalTrials.gov registry entry for NCT06793215 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT06793215 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06793215 about?
NCT06793215 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer". The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung ...
What is the current status of trial NCT06793215?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2025-10-24. Estimated completion is 2030-10-31.
What conditions does trial NCT06793215 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer.
What interventions are being tested in trial NCT06793215?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Divarasib (DRUG).
Who is sponsoring clinical trial NCT06793215?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06793215 being conducted?
This trial has 20 study locations across Alaska, California, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
-
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.